These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Ridker PM Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995 [TBL] [Abstract][Full Text] [Related]
3. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Ridker PM Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745 [TBL] [Abstract][Full Text] [Related]
6. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
7. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Martínez GJ; Celermajer DS; Patel S Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570 [TBL] [Abstract][Full Text] [Related]
8. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition. Satish M; Agrawal DK Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome. Pashun RA; Frishman WH Cardiol Rev; 2015; 23(5):252-60. PubMed ID: 25741604 [TBL] [Abstract][Full Text] [Related]
11. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502 [TBL] [Abstract][Full Text] [Related]
15. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
16. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Grebe A; Hoss F; Latz E Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500 [TBL] [Abstract][Full Text] [Related]
17. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. Kottoor SJ; Arora RR J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850 [TBL] [Abstract][Full Text] [Related]
18. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Ridker PM Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021 [TBL] [Abstract][Full Text] [Related]
19. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]